BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for Stem Cells

denovoMATRIX Introduces Ready-to-use, Chemically Defined Coated Cell Cultureware for Serum-free hMSC Expansion

By Leave a Comment

August 22, 2019, Dresden, Germany — Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells (hMSC) offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment.

Currently, bovine-derived fetal calf serum and human plasma-derived fibronectin are commonly used in hMSC culture. These biological extracts frequently reduce experimental reproducibility, and represent a liability for manufacturers of hMSC. To increase lot-to-lot consistency and eliminate the risk of transmission of xenogenic infectious agents, defined cell culture conditions including media and extracellular matrix mimetic coatings are essential.

denovoMATRIX has now introduced a ready-to-use coating composed of chemically defined components. The new product – termed myMATRIX MSC – promotes adhesion, proliferation and high viability of hMSC. According to the manufacturer, this novel surface supports long-term expansion of hMSCs over 10 passages and more than 25 population doublings. Furthermore, myMATRIX MSC enables expansion of hMSC in both serum-free and xeno-free media conditions.

Vision for the future?

Enabling animal-component free processes for large-scale manufacturing of hMSC. The field of cell-based therapies just took a step closer.

Read the application note about myMATRIX hMSC, including detailed expansion analysis of hMSC here.

About denovoMATRIX

denovoMATRIX develops and manufactures biomimetic coatings for the cultivation of human stem cells. Our focus is on enabling culture conditions for stem cells closer to the natural conditions found in the body. Our products offer a biologically relevant solution, which is both chemically defined, and modular for adapting to specific applications. Our vision is to enable human biology in vitro, beginning with Life Science research and onwards to cell therapies of the future.

Contact

denovoMATRIX GmbH
Christian Woiwod
Tatzberg 47/49
01307 Dresden
[email protected]

Do you have questions for denovoMATRIX? Ask them in the comments below.

GenCure announces breakthrough first run of 80-liter bioreactor

By Leave a Comment

Biomanufacturing CDMO among first to harvest adult stem cells at large scale

Human MSC Manufacturing

SAN ANTONIO, Texas – In a breakthrough for the regenerative medicine industry, GenCure announced today that its biomanufacturing services team has successfully completed production runs expanding and harvesting human mesenchymal stem cells (hMSCs) in an 80-liter bioreactor.  GenCure, a subsidiary of BioBridge Global (BBG), announced a major expansion of its biomanufacturing facilities in February of this year. [Read more…]

Biological Industries USA Adds Strategic Offering of Small Molecules to its Stem Cell Portfolio

By Leave a Comment

August 8, 2019 — CROMWELL, Conn. — Biological Industries USA (BI-USA), a division of Biological Industries Beit Haemek Israel (BI), and provider of cell culture tools for translational research, today announced the addition and sale of small molecules for stem cell applications; specifically for enhancing research in diabetes, neural disorders, and cardiovascular disease.

Small molecules can be used to modulate biological signals for a multitude of applications, including cellular reprogramming, stem cell self-renewal, and the differentiation of stem cells into specific lineages, altogether advancing the rapidly evolving field of translational cell therapy. [Read more…]

First iPSC-Derived CAR-T Therapy by CiRA and Takeda Nears Clinical Testing

By

− iCART Program Advances the Potential for a Highly Scalable, Lower Cost, Off-the-Shelf CAR T-Cell Therapy to Treat Cancer

KYOTO and OSAKA, Japan I July 16,2019 – The Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a novel induced pluripotent stem (iPS) cell-derived chimeric antigen receptor (CAR) T-cell therapy (iCART) has been transferred from their T-CiRA research collaboration to Takeda as the program begins process development toward clinical testing. Under the terms of the T-CiRA agreement, Takeda has the global rights to develop and commercialize the iCART product and CiRA will receive development and approval milestones. The teams will continue to collaborate as they prepare the iCART program for a clinical trial in 2021. [Read more…]

Forever Labs, Is It Worth $7,000 to Save Cells from Your Younger Self?

By

Forever LabsForever Labs is one of the first companies worldwide to offer stem cell storage for adults. Interestingly, there is a prolific market for the storage of newborn tissues, including umbilical cord blood, umbilical tissue, and placental blood and tissue.

However, storage for stem cells from adult sources, including fat (adipose) tissue and bone marrow, is extremely limited. 

The company was founded, because the management team believes stem cell therapies will be ubiquitous in the future, and when your time of need comes, your ideal donor will be your younger self. 

Are you interested to store your stem cells before you (and they) get too old?

If so, read on to enjoy this interview with Dr. Mark Katakowski, Ph.D., President and Chief Scientific Officer of Forever Labs. In it, we explore his background, the mission of Forever Labs, and the importance of storing young adult stem cells. 

[Read more…]

BioInformant's World-Class Clients